Arena to Get Second Shot at Approval

February 2nd, 2012 No comments »

Arena Pharmaceuticals Inc. (and its partner Esai Inc.) have announced that they have been informed by the Food and Drug Administration that an Advisory Committee meeting will be held in the second quarter on their weight loss drug candidate, lorcaserin.  Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin (NASDAQ:ARNA)  Arena is expected to produce information on efficacy and tumor development with their drug.

Competitive Food Sales in Schools Not Affect Obesity

February 2nd, 2012 No comments »

Most US middle and high schools sell soft drinks, candy and chips to their students. These practices have been widely criticized as contributing to childhood and adolescent obesity. However, a new study followed  approximately 19,450 children from fifth to eight grade. Researchers found the children’s weight gain was not associated with the introduction or the duration of exposure to competitive foods. This did not vary by gender, race/ethnicity or family socioeconomic status. Possible explanations are that children’s food preferences and dietary patterns are firmly established before adolescence. Also, schools are highly structured whereas home life may have more opportunities for snacking. http://www.asanet.org/images/journals/docs/pdf/soe/Jan12SOEFeature.pdf.

The Gene Pool is Getting Murky

February 2nd, 2012 No comments »

Copyright New York Times

Researchers have now found an entirely new line of ancestors of modern humans  - the Denisovans- whose genes we carry.  Gains in DNA Are Speeding Research Into Human Origins – NYTimes.com The article contains speculation that the mating between different early humans allowed for the transfer of genes helping the immune system. However, the archaic immune genetic material may be responsible for autoimmune diseases such as multiple sclerosis, arthritis and diabetes.

Why mention this? The point is that whenever someone mentions the influence of genetics of obesity, the common retort is that ‘the gene pool doesn’t change so fast.” The problems with this answer are (a) as indicated by the above study we are still sorting out what exactly is in the gene pool, (b) it ignores other recent findings showing that there are changes occurring more recently in our genes, (c) it ignores the long, 300 year picture of increasing height and weight in humans, and (d) it ignores the strong, developing evidence of the intrauterine environment and epigenetics.

Further evidence has just come out in a study of obesity across three generations. The researchers found that BMI is highly transmissible across generations, and especially involving the maternal line. The fundamental link between BMI of mother and child was not explained by shared environmental factors alone. Both mothers and fathers contribute equally to the child’s height. This was a prospective study with data collected from 3 generations of one family, with data taken prior to pregnancy and in early childhood. The authors conclude, “BMI in early childhood may be transmitted through a combination of genetic and intrauterine effects possibly operating via epigenetic mechanisms”.  Body mass index and height over three gene… [BMC Public Health. 2012] – PubMed – NCBI

 

Will ACOs Be Good For Patients With Obesity ?

February 2nd, 2012 No comments »

Accountable Care Organizations are predicted to replace health insurers in 20 years, according to 2 prominent health care policy makers, Ezekiel Emanuel and Jeffrey Liebman in the New York Times. The End of Health Insurance Companies – NYTimes.com.   

The authors point to a shrinking market of traditional insurers and the changes coming under health care reform. Mainly, they look to the model that the ACOs will be paid a fixed rate per enrollee, not on a fee for service basis, with a bonus for meeting quality goals. They will have an incentive to keep their people healthy and out of hospitals.

What are the implications for obesity prevention and treatment? Frankly, we have seen this type of prediction before with the development of health maintenance organizations in the 1990s. The authors recognize this but predict that the information systems today will overcome the restrictive practices of HMOs. In theory, it would seem ACOs would want to encourage their enrollees to achieve as healthy weight as possible. On the other hand, perhaps they will find a way to avoid enrolling patients with obesity or limit services to them.  We wait with bated breath.

Increasing Rates of Some Cancers Associated with Obesity

January 28th, 2012 No comments »

Increasing rates of some cancers may be associated with obesity. Cancers with increasing incidence trends in… [CA Cancer J Clin. 2012] – PubMed – NCBI

Powerful New Study Underscores Obesity-Pain Relationship

January 28th, 2012 No comments »

A new survey of one million Americans found a high association between obesity and pain. Obesity and Pain Are Associated in t… [Obesity (Silver Spring). 2012] – PubMed – NCBIThey found the association was “robust” among both men and women. This survey involved an unusually high number of subjects and confirmed earlier studies.

Child Labor Laws Responsible for Childhood Obesity?

January 28th, 2012 No comments »

Well, here’s a new one. Senator Charles Grassley (R-Iowa) is suggesting that child labor laws are responsible for the rise in childhood obesity. Grassley was criticizing a Department of Labor regulation that children could only work on farms owned by their parents when he decided to open up this novel line. Political Animal – Leave child-labor laws alone

FDA Approves Once Weekly Drug for Diabetes; Shows Weight Loss

January 28th, 2012 No comments »

The Food and Drug Administration has approved Amylin Pharmaceutical’s Bydureon for thetreatment of type 2 diabetes. This is the first once-weekly treatment for type 2 diabetes. It is hoped that this feature will lead to higher adherence to the treatment regimen, although as with Byetta, it is injectable. The drug is exenatide, a GLP-1 receptor agonist. Study results showed an improvement in glycemic control.  A1C levels, a measure of blood sugar, decreased an average of 1.6 points.

Many patients with Type 2 diabetes are also overweight or obese. Many drugs for type 2 diabetes actually cause weight gain. The advantage of Bydureon (and its daily administered counterpart, Byetta) is that patients taking Bydureon can achieve weight loss, in addition to improvements in glycemia, blood pressure, and cholesterol in both overweight and obesity subjects with and without type 2 diabetes. Effects of glucagon-like peptide-1 receptor agonists on … [BMJ. 2012] – PubMed – NCBI

A very small study of 12 children and adolescents with extreme obesity also showed significant improvements, suggesting the need for a larger study. Exenatide as a weight-loss therapy i… [Obesity (Silver Spring). 2012] – PubMed – NCBI

More information is available at www.BYDUREON.com.